| P/E (FY) | 29.0 | Sales (TTM) | €596.9M |
| Earnings (TTM) | €43.4M | ROE | 10.89% |
| Net Margin | 7.27% | ROIC | 20.59% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | −8.42% | Sales Growth 3Y | −4.24% |
EL.En. produces, develops, distributes, and sells laser systems in Italy, the rest of Europe, and internationally, serving both the medical and industrial sectors. Its products include solid-state, semiconductor, fiber, dye, and CO2 lasers, along with radio-frequency, microwave, and frequency-conversion systems. The company also conducts medical research in areas such as body shaping, dermatology, and hair removal, and industrial research in metal cutting and marking. Founded in 1981, it is headquartered in Calenzano, Italy.
| Market Cap | $1.41B | Trading Days | 4151 |
| 52W High | 17.61 |
| 52W Low | 10.34 |
| % Off High | −12.72% |
| YTD | 12.28% | 1Y | 26.45% |
| 3Y | 49.66% | 5Y | 54.15% |
| 10Y | 376.63% | Since incept. (ann.) | 21.24% |
| Ann. Volatility (1Y) | 28.75% | Ann. Volatility (3Y) | 38.40% |
| Sharpe (1Y) | 1.00 | Sharpe (3Y) | 0.58 |
| Max Drawdown (1Y) | −21.39% | Max Drawdown (3Y) | −39.82% |
| Beta (3Y, vs SPY) | 1.49 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| AVBP | ArriVent BioPharma, Inc. | $1.40B | — |
| PNTG | Pennant Group, Inc. | $1.43B | 48.9 |
| CDRE | Cadre Holdings, Inc. | $1.43B | 32.7 |
| HROW | HARROW, INC. | $1.44B | — |
| PRGO | PERRIGO Co plc | $1.44B | — |
| XERS | Xeris Biopharma Holdings, Inc. | $1.45B | — |
| XNCR | Xencor Inc | $1.45B | — |
| VIR | Vir Biotechnology, Inc. | $1.46B | — |
| TRAX | First Tracks Biotherapeutics, Inc. | $1.46B | — |
| ATEC | Alphatec Holdings, Inc. | $1.46B | — |
| MLTX | MoonLake Immunotherapeutics | $1.35B | — |
| GDS.PA | RAMSAY GENERALE DE SANTE | $1.35B | — |
